

Nakinadines B–F: new pyridine alkaloids with a β -amino acid moiety from sponge *Amphimedon* sp.

Takami Nishi^a, Takaaki Kubota^a, Jane Fromont^b, Takuma Sasaki^c, Jun'ichi Kobayashi^{a,*}

^a Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

^b Western Australian Museum, Locked Bag 49, Welshpool DC, WA 6986, Australia

^c School of Pharmacy, Aichi Gakuin University, 2-11 Semori-dori, Chikusa-ku, Nagoya 464-865, Japan

Received 17 November 2007; received in revised form 28 January 2008; accepted 29 January 2008

Available online 2 February 2008

Abstract

Five new 3-alkylpyridine alkaloids with a β -amino acid moiety, nakinadines B–F (**1**–**5**), have been isolated from an Okinawan marine sponge *Amphimedon* sp. (SS-1059), and the structures and stereochemistry were elucidated by spectroscopic data. Nakinadines B (**1**) and C (**2**) showed modest cytotoxicity.

© 2008 Elsevier Ltd. All rights reserved.

Keywords: Sponge; Alkaloid; Pyridine; β -Amino acid; Nakinadines B–F

1. Introduction

Marine sponges are a rich source of bioactive secondary metabolites with unprecedented skeletons. A number of 3-alkylpyridine alkaloids have been isolated from marine sponges of several genera.¹ Most of them possess a long aliphatic chain with a various nitrogen-containing terminus,² some of which have dimeric or polymeric structures of 3-alkylpyridine.³ During our continuing search for bioactive substances from marine sponges,⁴ we previously isolated cytotoxic pyridine alkaloids from sponges of the genera *Theonella*,⁵ *Nyphates*,⁶ *Amphimedon*,⁷ and *Cribrochalina*.⁸ More recently, new 3-alkylpyridine alkaloids with a β -amino acid moiety, nakinadines B–F (**1**–**5**), have been isolated together with nakinadine A⁴ (**6**) from an Okinawan marine sponge *Amphimedon* sp. (SS-1059). Here we describe the isolation and structural elucidation of nakinadines B–F (**1**–**5**).


2. Results and discussion

The sponge *Amphimedon* sp. (SS-1059) collected off Naki-jin, Okinawa was extracted with MeOH. EtOAc-soluble materials of the MeOH extract were subjected to a silica gel column (CHCl₃/MeOH), in which a fraction eluted with CHCl₃/MeOH (7:3) was purified by C₁₈ HPLC (MeOH/H₂O) to afford nakinadines B (**1**, 0.004%, wet weight) and C (**2**, 0.005%). The fraction eluted with CHCl₃/MeOH (9:1) in the silica gel column was further purified by an amino silica gel column (CHCl₃/MeOH) followed by C₁₈ HPLC (MeOH/H₂O) to afford nakinadines D (**3**, 0.001%, wet weight), E (**4**, 0.002%), and F (**5**, 0.001%) together with nakinadine A⁴ (**6**, 0.001%).

Nakinadine B (**1**) was revealed to have the molecular formula, C₂₇H₄₀N₂O₂, by HRESIMS [*m/z* 423.2998 (M–H)⁺, Δ –0.3 mmu]. Aromatic proton signals [H-2 and H-6, δ_{H} 8.43; H-4, δ_{H} 7.48; H-5, δ_{H} 7.18; H-25 and H-29, δ_{H} 7.33 (2H); H-26 and H-28, δ_{H} 7.26 (2H); H-27, δ_{H} 7.20] in the ¹H NMR spectrum and five sp² carbon signals (C-2, δ_{C} 149.8; C-3, δ_{C} 138.4; C-4, δ_{C} 135.8; C-5, δ_{C} 123.2; C-6, δ_{C} 147.1) and four sp² carbon signals (C-24, δ_{C} 135.9; C-25 and C-29, δ_{C} 128.7 (2C); C-26 and C-28, δ_{C} 128.2 (2C); C-27, δ_{C} 127.3) in the ¹³C NMR spectrum

* Corresponding author. Tel.: +81 11 706 3239; fax: +81 11 706 4989.

E-mail address: jkobay@pharm.hokudai.ac.jp (J. Kobayashi).



Stereochemistries for **3–6** denote relative one.

suggested that **1** possessed a 3-alkylpyridine ring and a phenyl group. The ^{13}C NMR data disclosed the presence of a carbonyl carbon (δ_{C} 176.6). IR absorptions at 3400–2600 and 1733 cm^{-1} indicated the presence of carboxylic acid functionality. The ^1H and ^{13}C NMR data suggested that CH_2 -19 (δ_{H} 2.89 (2H); δ_{C} 47.9) and CH_2 -21 (δ_{H} 3.47 and 2.89; δ_{C} 51.1) were adjacent to a nitrogen atom.

The gross structure of **1** was elucidated by analyses of 2D NMR data in CDCl_3 (Fig. 1). The ^1H – ^1H COSY and TOCSY spectra revealed connectivities of five structural fragments, **a** (C-2 to C-6), **b** (C-7 to C-8), **c** (C-18 to C-19), **d** (C-21 to C-22), and **e** (C-25 to C-29). HMBC correlations from H-7 to C-2, C-3, and C-4 suggested the connectivity of C-7 to C-3. The connectivity of C-19 to C-21 through a nitrogen atom was implied by HMBC cross-peaks for H_2 -19 to C-21. HMBC cross-

peaks for H-22 to C-23 and C-25, and H-29 to C-24 indicated that a carboxyl and a phenyl group were both attached to C-22.

The connection of C-8 to C-18 via a long alkyl chain was elucidated on the basis of fragmentation patterns of the ESIMS/MS spectrum of **1** (Fig. 2). Thus, the gross structure of nakinadine B was elucidated to be **1**.

To assign the absolute configuration at C-22, the carboxy group at C-22 in **1** was converted into the (*S*)- and (*R*)-phenylglycine methyl ester (PGME) amides. The $\Delta\delta$ [δ (*S*-PGME amide)– δ (*R*-PGME amide)] values obtained from the ^1H NMR spectra of the PGME amides suggested that the absolute configuration at C-22 in **1** was *S* (Fig. 3).⁹




Figure 1. Selected 2D NMR correlations for nakinadine B (**1**).




Figure 2. Fragmentation patterns of nakinadine B (**1**) in ESIMS/MS [parent ion; at m/z 425 ($\text{M}+\text{H}^+$)].




Figure 3. $\Delta\delta$ values [$\Delta\delta$ (in ppm) $\delta_S - \delta_R$] obtained for (*S*)- and (*R*)-PGME amides of nakinadine B (**1**).

Nakinadine C (**2**) was revealed to have the molecular formula, $C_{28}H_{40}N_2O_2$, by HRESIMS [m/z 437.3163 ($M+H$) $^+$, Δ -0.6 mmu]. 1H and ^{13}C NMR data of **2** were similar to those of nakinadine B (**1**), except for the presence of signals due to a double bond in **2**. *Z*-Geometry of an olefin at C-9 was assigned from chemical shifts of allylic carbons [C-8, δ_C 28.7; C-11, δ_C 26.7].¹⁰ The 1H - 1H COSY, TOCSY, and HMBC spectra revealed connectivities from a β -substituted pyridine ring to C-12 and C-19 to C-30 (Fig. 4). The fragmentation patterns obtained from ESIMS/MS spectrum of **2** disclosed connectivities from C-12 to C-19 (Fig. 5). The $\Delta\delta$ values obtained from the 1H NMR spectra of the PGME amides of **2** showed the same pattern as those of **1**, suggesting that the absolute configuration at C-23 of **2** was *S*. Thus, the stereostructure of nakinadine C was elucidated to be **2**.




Figure 4. Selected 2D NMR correlations for nakinadine C (**2**).




Figure 5. Fragmentation patterns of nakinadine C (**2**) in ESIMS/MS [parent ion; at m/z 437 ($M+H$) $^+$].




Figure 7. Rotation model for C-20 to C-21 of nakinadine D (**3**).

Nakinadine D (**3**) was revealed to have the molecular formula, $C_{43}H_{65}N_3O_2$, by HRESIMS [m/z 656.5179 ($M+H$) $^+$, Δ $+2.4$ mmu]. 1H and ^{13}C NMR data of **3** were similar to those of nakinadine A (**6**), except for lack of signals due to a double bond in **6**. Analysis of the ESIMS/MS spectrum of **3** revealed connectivities from two pyridine rings to β -amino acid moiety (Fig. 6). Thus, the gross structure of nakinadine D was assigned as **3**.

The relative stereochemistry of **3** was deduced from NOESY correlations and *J*-values¹¹ as shown in Figure 7. A *gauche* relation for H-20 and H-21 was deduced from the NOESY cross-peak for H-20/H-21 and $^3J_{H-20/H-21}$ (2 Hz). The NOESY cross-peaks for H-20/H-24 and H-20/H-25 suggested a *gauche* relation for H-20 and a phenyl group. A large coupling constant ($^3J_{H-21/C-18'}=8$ Hz), which was obtained from the HETLOC spectrum of **3**, indicated an *anti* relation for H-21 and C-18' (Fig. 7).

The spectral data of nakinadine E (**4**) were almost identical with those of nakinadine D (**3**), except for the molecular weight derived from ESIMS [m/z 670 ($M+H$) $^+$]. The molecular formula of **4**, $C_{44}H_{67}N_3O_2$, revealed by HRESIMS [m/z 670.5315 ($M+H$) $^+$, Δ $+0.3$ mmu] suggested that the carbon chain of **4** was longer by one methylene unit as compared with that of **3**. The fragmentation patterns obtained from ESIMS/MS data of **4** (Fig. 8) also supported the proposed structure of nakinadine E (**4**). The relative stereochemistry at C-21 and C-22 of **4** was elucidated to be the same as those of **3** on the basis of NOESY correlations (H-21 to H-22, H-25, and H-26) and *J*-values ($^3J_{H-21/H-22}=2$ Hz and $^3J_{H-22/C-18'}=8$ Hz) of **4**. Thus, the structure of nakinadine E was elucidated to be **4**.

The spectral data of nakinadine F (**5**) were similar to those of nakinadine A (**6**). The molecular formula, $C_{46}H_{67}N_3O_2$, revealed from HRESIMS [m/z 694.5313 ($M+H$) $^+$, Δ $+0.2$ mmu] and the 1H and ^{13}C NMR spectra indicated that




Figure 6. Fragmentation patterns of nakinadine D (**3**) in ESIMS/MS [parent ion; (A) at m/z 656 ($M+H$) $^+$, (B) at m/z 520 ($M-C_8H_9O_2+H$) $^+$].




Figure 8. Fragmentation patterns of nakinadine E (**4**) in ESIMS/MS [parent ion; (A) at m/z 670 ($M+H$)⁺, (B) at m/z 534 ($M-C_8H_9O_2+H$)⁺].




Figure 9. Fragmentation patterns of nakinadine F (**5**) in ESIMS/MS [parent ion; (A) at m/z 694 ($M+H$)⁺, (B) at m/z 558 ($M-C_8H_9O_2+H$)⁺].

the carbon chain of **5** was shorter by one methylene unit as compared with that of **6**, and **5** had two *Z* double bonds. Analysis of the ESIMS/MS spectrum of **5** revealed connectivities from two pyridine rings to β -amino acid moiety including position of two double bonds (Fig. 9). The relative stereochemistry of a β -amino acid moiety in **5** was elucidated to be the same as those of **3** on the basis of NOESY correlations (H-22 to H-23, H-26, and H-27) and *J*-values ($^3J_{H-22/H-23}=2$ Hz and $^3J_{H-23/C-19'}=8$ Hz) of **5**. Thus, the structure of nakinadine F was assigned as **5**.

Nakinadines B (**1**) and C (**2**) showed cytotoxicity against L1210 murine leukemia (IC₅₀, 3.0 and 5.0 μ g/mL, respectively) and KB human epidermoid carcinoma cells (IC₅₀, 7.0 and >10 μ g/mL, respectively) in vitro, while nakinadines D (**3**), E (**4**), and F (**5**) did not show such activity (IC₅₀>10 μ g/mL).

3. Experimental

3.1. General

IR and UV spectra were recorded on a JASCO FT/IR-230 and a Shimadzu UV-1600PC spectropolarimeters. ¹H and ¹³C NMR spectra were recorded on a Bruker AMX-600 spectrometer using 2.5 mm micro cells (Shigemi Co., Ltd). The 7.26 and 77.0 ppm resonances of residual CDCl₃ were used as internal

references for ¹H and ¹³C NMR spectra, respectively. ESI mass spectra were obtained on a JEOL JMS-700TZ spectrometer.

3.2. Sponge description

The sponge *Amphimedon* sp. (SS-1059; order Haplosclerida; family Niphatidae) was collected off Nakijin, Okinawa and kept frozen until used. The sponge is thick walled tube with a dense internal skeleton. Specimen has a central oscule and canal. Sponge has a reticulate fiber skeleton, close meshed, centrally cored with spicules. Primary meshes are slightly elongate. Primary fibers are multispicular, approximately 60 μ m wide cored by approximately 5 spicules. Secondary fibers are occasionally unispicular, 40 μ m wide cored by 1–2 spicules. Spicules are oxeas, 105 $\times$ 5 μ m. Exterior surface is smooth, shiny.

3.3. Extraction and isolation

The sponge (SS-1059, 0.2 kg, wet weight) was extracted with MeOH (1.0 L $\times$ 3), and the extract was partitioned between EtOAc and H₂O. The EtOAc-soluble materials were subjected to a silica gel column (CHCl₃/MeOH, 10:0 to 0:10) to give alkaloidal fractions. The fraction eluted with CHCl₃/MeOH (7:1) was purified by reversed-phase HPLC (Luna 5u phenyl–hexyl,

250×10 mm; eluent, MeOH/H₂O, 85:15; flow rate, 1.5 mL/min; UV detection at 263 nm) to afford nakinadines B (**1**, 0.0037% wet weight, *t_R* 19 min) and C (**2**, 0.0045%, *t_R* 21 min). The fraction eluted with CHCl₃/MeOH (9:1) was separated by an amino silica gel column chromatography (CHCl₃/MeOH, 10:0 to 0:10) followed by reversed-phase HPLC (Luna 5u phenyl–hexyl, 250×10 mm; eluent, MeOH/H₂O, 89:11; flow rate, 1.0 mL/min; UV detection at 263 nm) to afford nakinadines D (**3**, 0.0011%, *t_R* 12 min), E (**4**, 0.0022%, *t_R* 15 min), F (**5**, 0.0022%, *t_R* 18 min), and A (**6**, 0.0011%, *t_R* 12 min).

3.3.1. Nakinadine B (**1**)

Colorless oil; UV (MeOH) $\lambda_{\max}$ 257 (ϵ 3100), 263 (3300), and 270 (2900) nm; IR (film) $\nu_{\max}$ 3360, 3190, 2910, and 1733 cm⁻¹; ¹H NMR (CDCl₃) δ 8.43 (2H, m), 7.48 (m), 7.33 (2H, m), 7.26 (2H, m), 7.20 (m), 7.18 (m), 4.10 (br s), 3.47 (br s), 2.89 (3H, br s), 2.59 (2H, m), 1.60 (2H, m), 1.0–1.4 (20H, m); ¹³C NMR (CDCl₃) δ 176.6 (s), 149.8 (d), 147.1 (d), 138.4 (s), 135.9 (s), 135.8 (d), 128.7 (2C, d), 128.2 (2C, d), 127.3 (d), 123.2 (d), 51.1 (t), 50.8 (d), 47.9 (t), 33.0 (d), 29–30 (11C, t), 26.8 (t); ESIMS (neg.) *m/z* 423 (M–H)⁻; HRESIMS (neg.) *m/z* 423.2998 (M–H)⁻, Δ –0.3 mmu.

3.3.2. (S)-PGME amide of nakinadine B (**1**)

To an ice cooled DMF solution (1 mL) of **1** (1.0 mg) and (S)-PGME (1.0 mg) were added PyBOP[®] (benzotriazole-1-yl-oxytrispyrrolidiniumphosphoniumhexafluorophosphate) (2.0 mg), HOBt (1-hydroxybenzotriazole) (1.0 mg), and *N*-methylmorpholine (50 μ L), and stirring was continued at rt for 18 h. After addition of 5% HCl, the mixture was extracted with EtOAc (2.5 mL). The extract was washed with satd NaHCO₃ aq and brine, and then concentrated in vacuo. The residue was subjected to a silica gel column (CHCl₃/MeOH, 10:0 to 0:10) to give the (S)-PGME amide of **1** (0.6 mg). (S)-PGME amide of nakinadine B (**1**); colorless amorphous solid; ¹H NMR (CDCl₃) δ 8.42 (2H, m), 7.85 (NH, d), 7.47 (m), 7.36 (5H, m), 7.31 (2H, m), 7.29 (2H, m), 7.24 (m), 7.18 (m), 5.50 (m), 3.79 (m), 3.66 (3H, s), 3.24 (m), 2.95 (3H, m), 2.58 (2H, m), 1.0–1.8 (22H, m); ESIMS (pos.) *m/z* 572 (M+H)⁺.

3.3.3. (R)-PGME amide of nakinadine B (**1**)

The (R)-PGME amide of **1** (0.5 mg) was obtained from **1** (1.0 mg) according to the same procedure as described for the preparation of (S)-PGME amide of **1**. (R)-PGME amide of nakinadine B (**1**); colorless amorphous solid; ¹H NMR (CDCl₃) δ 8.42 (2H, m), 7.85 (NH, d), 7.47 (m), 7.34 (5H, m), 7.32 (2H, m), 7.29 (2H, m), 7.24 (m), 7.18 (m), 5.51 (m), 3.76 (m), 3.66 (3H, s), 3.21 (m), 2.94 (3H, m), 2.58 (2H, m), 1.0–1.8 (22H, m); ESIMS (pos.) *m/z* 572 (M+H)⁺.

3.3.4. Nakinadine C (**2**)

Colorless oil; UV (MeOH) $\lambda_{\max}$ 258 (ϵ 3200), 263 (3300), and 269 (3000) nm; IR (film) $\nu_{\max}$ 3350, 3200, 2920, and 1733 cm⁻¹; ¹H NMR (CDCl₃) δ 8.44 (2H, m), 7.49 (m), 7.33 (2H, m), 7.25 (2H, m), 7.20 (m), 7.18 (m), 5.37 (2H, m), 4.11 (br s), 3.49 (br s), 2.86 (br s), 2.82 (2H, br s), 2.65 (2H, t, *J*=7.4 Hz), 2.35 (2H, dt, *J*=7.4 and 6.7 Hz), 1.92 (2H, dt,

J=7.1 and 6.7 Hz), 1.61 (2H, br s), 1.0–1.4 (14H, m); ¹³C NMR (CDCl₃) δ 176.7 (s), 149.9 (d), 147.2 (d), 137.3 (s), 135.8 (s), 135.8 (d), 131.4 (d), 128.7 (2C, d), 128.2 (2C, d), 127.7 (d), 127.3 (d), 123.2 (d), 51.1 (t), 50.8 (d), 47.9 (t), 33.0 (t), 29–30 (7C, t), 28.7 (t), 27.2 (t), 26.7 (t); ESIMS (neg.) *m/z* 437 (M+H)⁺; HRESIMS (pos.) *m/z* 437.3163 (M+H)⁺, Δ –0.6 mmu.

3.3.5. (S)-PGME amide of nakinadine C (**2**)

The (S)-PGME amide of **2** (0.4 mg) was obtained from **2** (1.0 mg) according to the same procedure as described for the preparation of (S)-PGME amide of **1**. (S)-PGME amide of nakinadine C (**2**); colorless amorphous solid; ¹H NMR (CDCl₃) δ 8.42 (2H, m), 7.85 (NH, d), 7.47 (m), 7.36 (5H, m), 7.31 (2H, m), 7.29 (2H, m), 7.24 (m), 7.18 (m), 5.53 (m), 5.34 (2H, m), 3.79 (m), 3.69 (3H, s), 3.24 (m), 2.95 (3H, m), 2.61 (2H, m), 2.31 (2H, m), 1.95 (2H, m), 1.0–1.8 (16H, m); ESIMS (pos.) *m/z* 584 (M+H)⁺.

3.3.6. (R)-PGME amide of nakinadine C (**2**)

The (R)-PGME amide of **2** (0.5 mg) was obtained from **2** (1.0 mg) according to the same procedure as described for the preparation of (S)-PGME amide of **1**. (R)-PGME amide of nakinadine C (**2**); colorless amorphous solid; ¹H NMR (CDCl₃) δ 8.42 (2H, m), 7.85 (NH, d), 7.47 (m), 7.34 (5H, m), 7.32 (2H, m), 7.29 (2H, m), 7.24 (m), 7.18 (m), 5.54 (m), 5.34 (2H, m), 3.76 (m), 3.66 (3H, s), 3.21 (m), 2.94 (3H, m), 2.61 (2H, m), 2.31 (2H, m), 1.95 (2H, m), 1.0–1.8 (16H, m); ESIMS (pos.) *m/z* 584 (M+H)⁺.

3.3.7. Nakinadine D (**3**)

Colorless oil; UV (MeOH) $\lambda_{\max}$ 258 (ϵ 4700), 263 (5000), and 270 (4400) nm; IR (film) $\nu_{\max}$ 3200, 2853, and 1725 cm⁻¹; ¹H NMR (CDCl₃) δ 8.44 (4H, m), 7.49 (2H, m), 7.32 (4H, m), 7.20 (2H, m), 7.19 (m), 3.84 (br s), 2.98 (br s), 2.82 (m), 2.72 (m), 2.60 (4H, t, *J*=7.8 and 7.5 Hz), 1.1–1.7 (42H, m); ¹³C NMR (CDCl₃) δ 176.0 (s), 149.6 (2C, d), 146.8 (2C, d), 136.9 (2C, s), 135.8 (s), 135.5 (2C, d), 129.4 (2C, d), 128.2 (2C, d), 127.0 (d), 122.9 (2C, d), 59.5 (d), 51.9 (d), 44.9 (t), 32.7 (2C, t), 30.8 (2C, t), 28–30 (17C, t), 26.9 (t), 26.6 (t); ESIMS (pos.) *m/z* 656 (M+H)⁺; HRESIMS (pos.) *m/z* 656.5179 (M+H)⁺, Δ +2.4 mmu.

3.3.8. Nakinadine E (**4**)

Colorless oil; UV (MeOH) $\lambda_{\max}$ 259 (ϵ 4900), 263 (5100), and 269 (4500) nm; IR (film) $\nu_{\max}$ 3200, 2853, and 1725 cm⁻¹; ¹H NMR (CDCl₃) δ 8.41 (4H, m), 7.50 (2H, m), 7.33 (4H, m), 7.21 (2H, m), 7.20 (m), 3.87 (br s), 3.05 (br s), 2.85 (m), 2.72 (m), 2.61 (4H, m), 1.0–1.8 (44H, m); ¹³C NMR (CDCl₃) δ 176.0 (s), 149.6 (2C, d), 146.8 (2C, d), 136.9 (2C, s), 135.8 (s), 135.5 (2C, d), 129.4 (2C, d), 128.2 (2C, d), 127.0 (d), 122.9 (2C, d), 59.5 (d), 51.9 (d), 44.9 (t), 32.7 (2C, t), 30.8 (2C, t), 28–30 (18C, t), 26.9 (t), 26.6 (t); ESIMS (pos.) *m/z* 670 (M+H)⁺; HRESIMS (pos.) *m/z* 670.5315 (M+H)⁺, Δ +0.3 mmu.

3.3.9. Nakinadine F (5)

Colorless oil; UV (MeOH) $\lambda_{\max}$ 258 (ϵ 4900), 264 (5200), and 270 (4600) nm; IR (film) $\nu_{\max}$ 3200, 2853, and 1725 cm^{-1} ; ^1H NMR (CDCl_3) δ 8.40 (4H, m), 7.49 (2H, m), 7.31 (4H, m), 7.20 (2H, m), 7.18 (m), 5.38 (4H, m), 3.84 (br s), 3.01 (br s), 2.80 (m), 2.70 (m), 2.65 (2H, m), 2.60 (2H, m), 2.35 (4H, m), 1.0–1.7 (36H, m); ^{13}C NMR (CDCl_3) δ 176.0 (s), 149.6 (2C, d), 146.8 (2C, d), 136.9 (2C, s), 135.8 (s), 135.5 (2C, d), 131.1 (2C, d), 129.4 (2C, d), 128.2 (2C, d), 127.4 (2C, d), 127.0 (d), 122.9 (2C, d), 59.5 (d), 51.9 (d), 44.9 (t), 32.7 (2C, t), 28.4 (2C, t), 28–30 (14C, t), 26.9 (3C, t), 26.6 (t); ESIMS (pos.) m/z 694 ($\text{M}+\text{H}$) $^+$; HRESIMS (pos.) m/z 694.5313 ($\text{M}+\text{H}$) $^+$, Δ +0.2 mmu.

Acknowledgements

Authors thank Z. Nagahama and K. Uehara for their help with collection of the sponge, Ms. S. Oka, Center for Instrumental Analysis, Hokkaido University, for measurements of ESIMS. This work was partly supported by a grant from the Uehara Memorial Foundation, the Yakult Bio-Science Foundation, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References and notes

- Blunt, J. W.; Copp, B. R.; Hu, W.-P.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. *Nat. Prod. Rep.* **2007**, *24*, 31–86.

- (a) Quiñoà, E.; Crews, P. *Tetrahedron Lett.* **1987**, *28*, 2467–2468; (b) Sakemi, S.; Totton, L. E.; Sun, H. H. *J. Nat. Prod.* **1990**, *53*, 995–999; (c) Stierle, D. B.; Faulkner, D. J. *J. Nat. Prod.* **1991**, *54*, 1134–1136; (d) Carroll, A. R.; Scheuer, P. J. *Tetrahedron* **1990**, *46*, 6637–6644; (e) Matsunaga, S.; Shinoda, K.; Fusetani, N. *Tetrahedron Lett.* **1993**, *34*, 5953–5954; (f) Wang, G.-Y.-S.; Kuramoto, M.; Uemura, D. *Tetrahedron Lett.* **1996**, *37*, 1813–1816.
- (a) Schmitz, F. J.; Hollenbeak, K. H.; Campbell, D. C. *J. Org. Chem.* **1978**, *43*, 3916–3922; (b) Fusetani, N.; Yasumuro, K.; Matsunaga, S.; Hirota, H. *Tetrahedron Lett.* **1989**, *30*, 6891–6894; (c) Talpir, R.; Rudi, A.; Ilan, M.; Kashman, Y. *Tetrahedron Lett.* **1992**, *33*, 3033–3034; (d) Davies-Coleman, M. T.; Faulkner, D. J.; Dubowchik, G. M.; Roth, G. P.; Polson, C.; Fairchild, C. *J. Org. Chem.* **1993**, *58*, 5925–5930.
- Kubota, T.; Nishi, T.; Fukushi, E.; Kawabata, J.; Fromont, J.; Kobayashi, J. *Tetrahedron Lett.* **2007**, *48*, 4983–4985.
- Kobayashi, J.; Murayama, T.; Ohizumi, Y.; Sasaki, T.; Ohta, T.; Nozoe, S. *Tetrahedron Lett.* **1989**, *30*, 4833–4836.
- (a) Kobayashi, J.; Murayama, T.; Kosuge, S.; Kanda, F.; Ishibashi, M.; Kobayashi, H.; Ohizumi, Y.; Ohta, T.; Nozoe, S.; Sasaki, T. *J. Chem. Soc., Perkin Trans. 1* **1990**, 3301–3303; (b) Kobayashi, J.; Zeng, C.-M.; Ishibashi, M.; Shigemori, H.; Sasaki, T.; Mikami, Y. *J. Chem. Soc., Perkin Trans. 1* **1992**, 1291–1294.
- (a) Tsuda, M.; Hirano, K.; Kubota, T.; Kobayashi, J. *Tetrahedron Lett.* **1999**, *40*, 4819–4820; (b) Hirano, K.; Kubota, T.; Tsuda, M.; Mikami, Y.; Kobayashi, J. *Chem. Pharm. Bull.* **2000**, *48*, 974–977; (c) Ishiyama, H.; Tsuda, M.; Endo, T.; Kobayashi, J. *Molecules* **2005**, *10*, 312–316.
- (a) Kariya, Y.; Kubota, T.; Fromont, J.; Kobayashi, J. *Tetrahedron Lett.* **2006**, *47*, 997–998; (b) Kariya, Y.; Kubota, T.; Fromont, J.; Kobayashi, J. *Bioorg. Med. Chem.* **2006**, *14*, 8415–8419.
- Nagai, Y.; Kusumi, T. *Tetrahedron Lett.* **1995**, *36*, 1853–1856.
- Vysotskii, M. V.; Imbs, A. B.; Popkov, A. A.; Latyshev, N. A.; Svetashev, V. I. *Tetrahedron Lett.* **1990**, *31*, 4367–4370.
- Matsumori, N.; Kaneno, D.; Murata, M.; Nakamura, H.; Tachibana, K. *J. Org. Chem.* **1999**, *64*, 866–876.